$12.3 Billion is the total value of Baker Brothers Advisors's 121 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 15.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corporation | $3,996,048,000 | -7.0% | 34,230,323 | +0.3% | 32.41% | -13.7% |
| SGEN | Seattle Genetics, Inc. | $2,487,928,000 | +5.2% | 45,725,556 | 0.0% | 20.18% | -2.5% | |
| ALXN | Alexion Pharmaceuticals, Inc. | $1,200,022,000 | +15.3% | 8,553,864 | 0.0% | 9.73% | +7.0% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $972,631,000 | +35.1% | 25,819,768 | 0.0% | 7.89% | +25.3% | |
| BMRN | BioMarin Pharmaceutical Inc. | $549,641,000 | +2.5% | 5,905,673 | 0.0% | 4.46% | -4.9% | |
| GHDX | Buy | Genomic Health, Inc. | $442,215,000 | -1.4% | 13,780,480 | +0.0% | 3.59% | -8.5% |
| BGNE | Buy | BeiGene, Ltd.sponsored adr | $403,332,000 | +144.0% | 3,898,431 | +6.1% | 3.27% | +126.4% |
| DBVT | DBV Technologies S.A.sponsored adr | $233,826,000 | +18.8% | 5,509,560 | 0.0% | 1.90% | +10.2% | |
| AQXP | Aquinox Pharmaceuticals, Inc. | $155,156,000 | +0.9% | 10,934,154 | 0.0% | 1.26% | -6.5% | |
| AAAP | Buy | Advanced Accelerator Applications S.A.sponsored ads | $151,689,000 | +74.9% | 2,243,262 | +1.0% | 1.23% | +62.3% |
| ONCE | Buy | Spark Therapeutics, Inc. | $123,409,000 | +56.7% | 1,384,130 | +5.0% | 1.00% | +45.3% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $85,145,000 | +75.1% | 2,348,840 | +34.1% | 0.69% | +62.6% |
| AMRN | Amarin Corporation plcsponsored adr new | $79,343,000 | -13.2% | 22,669,509 | 0.0% | 0.64% | -19.5% | |
| AVXS | Buy | AveXis, Inc. | $74,966,000 | +46.0% | 775,000 | +24.0% | 0.61% | +35.4% |
| BCRX | Buy | BioCryst Pharmaceuticals, Inc. | $73,346,000 | +12.6% | 13,997,172 | +19.5% | 0.60% | +4.4% |
| NVTA | Invitae Corporation | $68,292,000 | -2.0% | 7,288,300 | 0.0% | 0.55% | -9.0% | |
| ARRY | Buy | Array BioPharma Inc. | $64,126,000 | +383.1% | 5,213,528 | +228.7% | 0.52% | +348.3% |
| AKAOQ | Sell | Achaogen, Inc. | $61,996,000 | -40.6% | 3,886,878 | -19.1% | 0.50% | -44.9% |
| BLCM | Bellicum Pharmaceuticals, Inc. | $58,123,000 | -1.1% | 5,032,313 | 0.0% | 0.47% | -8.4% | |
| EXEL | Exelixis, Inc. | $50,447,000 | -1.6% | 2,082,012 | 0.0% | 0.41% | -8.7% | |
| HRTX | Buy | Heron Therapeutics, Inc. | $45,026,000 | +16.8% | 2,787,992 | +0.2% | 0.36% | +8.3% |
| Sell | Novavax, Inc.note 3.75% 2/1/2023 | $39,536,000 | -14.8% | 88,500,000 | -18.4% | 0.32% | -20.9% | |
| NBIX | Neurocrine Biosciences, Inc. | $37,790,000 | +33.2% | 616,682 | 0.0% | 0.31% | +23.4% | |
| BLUE | Sell | bluebird bio, Inc. | $33,162,000 | +4.7% | 241,441 | -19.9% | 0.27% | -2.9% |
| SGMO | Sell | Sangamo Therapeutics, Inc. | $31,701,000 | -12.4% | 2,113,376 | -48.6% | 0.26% | -18.7% |
| Acorda Therapeutics, Inc.note 1.75% 6/15/2021 | $31,574,000 | +5.3% | 35,083,000 | 0.0% | 0.26% | -2.3% | ||
| ABEO | Abeona Therapeutics Inc. | $28,718,000 | +166.4% | 1,684,364 | 0.0% | 0.23% | +147.9% | |
| HALO | Halozyme Therapeutics, Inc. | $27,469,000 | +35.5% | 1,581,424 | 0.0% | 0.22% | +26.0% | |
| CERS | Sell | Cerus Corporation | $26,604,000 | +3.5% | 9,745,209 | -4.8% | 0.22% | -4.0% |
| MRTX | Mirati Therapeutics, Inc. | $26,549,000 | +220.5% | 2,269,198 | 0.0% | 0.22% | +198.6% | |
| GLPG | Galapagos NVsponsored adr | $26,444,000 | +33.0% | 259,894 | 0.0% | 0.21% | +23.0% | |
| NTLA | Intellia Therapeutics, Inc. | $26,394,000 | +55.3% | 1,062,120 | 0.0% | 0.21% | +43.6% | |
| SAGE | Buy | Sage Therapeutics, Inc. | $25,262,000 | +52.3% | 405,485 | +94.6% | 0.20% | +41.4% |
| CBAY | Buy | CymaBay Therapeutics, Inc. | $24,114,000 | +224.1% | 2,991,775 | +131.6% | 0.20% | +201.5% |
| PGNX | Progenics Pharmaceuticals, Inc. | $23,190,000 | +8.4% | 3,150,808 | 0.0% | 0.19% | +0.5% | |
| MRUS | Merus N.V. | $23,049,000 | +25.4% | 1,160,014 | 0.0% | 0.19% | +16.1% | |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $22,984,000 | +29.8% | 10,306,757 | +0.1% | 0.19% | +20.0% |
| NeuroDerm Ltd. | $22,238,000 | +30.1% | 571,667 | 0.0% | 0.18% | +20.8% | ||
| INSM | Buy | Insmed Incorporated | $21,847,000 | +218.3% | 700,000 | +75.0% | 0.18% | +195.0% |
| IMGN | Sell | ImmunoGen, Inc. | $20,567,000 | -4.1% | 2,688,489 | -10.8% | 0.17% | -10.7% |
| XNCR | Xencor, Inc. | $19,988,000 | +8.6% | 872,072 | 0.0% | 0.16% | +0.6% | |
| AIMT | Aimmune Therapeutics, Inc. | $16,706,000 | +20.6% | 673,908 | 0.0% | 0.14% | +11.6% | |
| RXDX | Buy | Ignyta, Inc. | $16,045,000 | +73.0% | 1,299,199 | +45.0% | 0.13% | +60.5% |
| MYOK | Buy | MyoKardia, Inc. | $15,223,000 | +1062.1% | 355,264 | +255.3% | 0.12% | +1018.2% |
| New | BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 added | $15,193,000 | – | 15,000,000 | +100.0% | 0.12% | – | |
| AERI | Aerie Pharmaceuticals, Inc. | $14,549,000 | -7.5% | 299,356 | 0.0% | 0.12% | -14.5% | |
| FOMX | Foamix Pharmaceuticals Ltd. | $13,690,000 | +19.6% | 2,466,702 | 0.0% | 0.11% | +11.0% | |
| BioMarin Pharmaceutical Inc.note 0.75% 10/15/2018 | $13,634,000 | +0.6% | 12,228,000 | 0.0% | 0.11% | -5.9% | ||
| CPRX | Catalyst Pharmaceuticals, Inc. | $12,857,000 | -8.7% | 5,102,153 | 0.0% | 0.10% | -15.4% | |
| ACOR | New | Acorda Therapeutics, Inc. | $12,286,000 | – | 519,500 | +100.0% | 0.10% | – |
| NLNK | Buy | Newlink Genetics Corporation | $10,254,000 | +179.0% | 1,007,273 | +101.5% | 0.08% | +159.4% |
| LGND | Ligand Pharmaceuticals Incorporated | $9,992,000 | +12.2% | 73,386 | 0.0% | 0.08% | +3.8% | |
| ITCI | Intra-Cellular Therapies, Inc. | $9,613,000 | +27.1% | 609,166 | 0.0% | 0.08% | +18.2% | |
| LOXO | Sell | Loxo Oncology, Inc. | $8,849,000 | -20.2% | 96,062 | -30.5% | 0.07% | -25.8% |
| ASMB | Assembly Biosciences, Inc. | $8,730,000 | +69.1% | 250,000 | 0.0% | 0.07% | +57.8% | |
| AGIO | Agios Pharmaceuticals, Inc. | $8,588,000 | +29.7% | 128,666 | 0.0% | 0.07% | +20.7% | |
| SYRS | Syros Pharmaceuticals, Inc. | $8,462,000 | -8.5% | 574,835 | 0.0% | 0.07% | -14.8% | |
| ACHN | Achillion Pharmaceuticals, Inc. | $8,336,000 | -2.2% | 1,856,637 | 0.0% | 0.07% | -9.3% | |
| GLYC | GlycoMimetics, Inc. | $7,881,000 | +25.4% | 563,312 | 0.0% | 0.06% | +16.4% | |
| CFRX | Buy | ContraFect Corporation | $7,940,000 | +35.3% | 7,153,076 | +76.8% | 0.06% | +25.5% |
| ALKS | Alkermes plc | $7,639,000 | -12.3% | 150,251 | 0.0% | 0.06% | -18.4% | |
| GWPH | New | GW Pharmaceuticals plcads | $7,612,000 | – | 75,000 | +100.0% | 0.06% | – |
| VNDA | New | Vanda Pharmaceuticals Inc. | $7,588,000 | – | 423,884 | +100.0% | 0.06% | – |
| Buy | Nabriva Therapeutics plc | $7,684,000 | +109.5% | 938,235 | +168.1% | 0.06% | +93.8% | |
| DMTX | Dimension Therapeutics, Inc. | $7,511,000 | +313.8% | 1,251,881 | 0.0% | 0.06% | +281.2% | |
| Sell | Aegerion Pharmaceuticals, Inc.note 2.0% 8/15/2019 | $7,576,000 | -34.4% | 9,517,000 | -34.4% | 0.06% | -39.6% | |
| STML | Stemline Therapeutics, Inc. | $7,032,000 | +20.7% | 633,497 | 0.0% | 0.06% | +11.8% | |
| MGNX | MacroGenics, Inc. | $6,721,000 | +5.5% | 363,676 | 0.0% | 0.06% | -1.8% | |
| TTPH | New | Tetraphase Pharmaceuticals, Inc. | $6,395,000 | – | 935,000 | +100.0% | 0.05% | – |
| RIGL | Rigel Pharmaceuticals, Inc. | $6,398,000 | -7.0% | 2,518,882 | 0.0% | 0.05% | -13.3% | |
| SBPH | Spring Bank Pharmaceuticals, Inc. | $6,284,000 | +24.4% | 373,144 | 0.0% | 0.05% | +15.9% | |
| XLRN | Buy | Acceleron Pharma Inc. | $6,117,000 | +599.9% | 163,900 | +469.8% | 0.05% | +525.0% |
| GNMX | Buy | Aevi Genomic Medicine, Inc. | $5,728,000 | +166.2% | 4,546,426 | +181.0% | 0.05% | +142.1% |
| AGLE | Aeglea BioTherapeutics, Inc. | $5,609,000 | +28.0% | 1,137,872 | 0.0% | 0.04% | +18.4% | |
| Array BioPharma Inc.note 3.0% 6/1/2020 | $5,410,000 | +33.1% | 3,000,000 | 0.0% | 0.04% | +22.2% | ||
| LJPC | Sell | La Jolla Pharmaceutical Company | $5,380,000 | -64.2% | 154,675 | -69.4% | 0.04% | -66.4% |
| SELB | Selecta Biosciences, Inc. | $5,289,000 | -8.1% | 289,809 | 0.0% | 0.04% | -14.0% | |
| VYGR | New | Voyager Therapeutics, Inc. | $4,880,000 | – | 237,014 | +100.0% | 0.04% | – |
| EPZM | Epizyme, Inc. | $4,429,000 | +26.2% | 232,481 | 0.0% | 0.04% | +16.1% | |
| CMTA | New | Clementia Pharmaceuticals Inc. | $4,223,000 | – | 250,000 | +100.0% | 0.03% | – |
| ALBO | Albireo Pharma, Inc. | $4,190,000 | +1.7% | 200,000 | 0.0% | 0.03% | -5.6% | |
| ANAB | Sell | AnaptysBio, Inc. | $3,893,000 | +38.8% | 111,386 | -5.0% | 0.03% | +28.0% |
| Inotek Pharmaceuticals Corporationnote 5.75% 8/1/2021 | $3,904,000 | +31.1% | 5,000,000 | 0.0% | 0.03% | +23.1% | ||
| ADMS | Adamas Pharmaceuticals, Inc. | $3,655,000 | +21.1% | 172,630 | 0.0% | 0.03% | +15.4% | |
| VSAR | Sell | Versartis, Inc. | $3,521,000 | -87.8% | 1,437,214 | -13.5% | 0.03% | -88.5% |
| TNXP | Buy | Tonix Pharmaceuticals Holdings Corp. | $3,190,000 | +44.2% | 699,500 | +36.9% | 0.03% | +36.8% |
| AKTX | Akari Therapeutics plcsponsored adr | $3,051,000 | +33.2% | 496,901 | 0.0% | 0.02% | +25.0% | |
| NTRA | Natera, Inc. | $2,948,000 | +18.7% | 228,676 | 0.0% | 0.02% | +9.1% | |
| OVID | Ovid Therapeutics Inc. | $2,857,000 | -18.3% | 333,333 | 0.0% | 0.02% | -25.8% | |
| Protalix BioTherapeutics, Inc.note 4.5% 9/15/2018 | $2,576,000 | +0.2% | 3,423,000 | 0.0% | 0.02% | -4.5% | ||
| MDGL | Madrigal Pharmaceuticals, Inc. | $2,598,000 | +176.7% | 57,762 | 0.0% | 0.02% | +162.5% | |
| RARX | Ra Pharmaceuticals, Inc. | $2,598,000 | -22.1% | 177,952 | 0.0% | 0.02% | -27.6% | |
| TRVN | Trevena, Inc. | $2,423,000 | +10.9% | 950,000 | 0.0% | 0.02% | +5.3% | |
| KPTI | Karyopharm Therapeutics Inc. | $2,383,000 | +21.3% | 216,990 | 0.0% | 0.02% | +11.8% | |
| NVAX | Novavax, Inc. | $2,280,000 | -0.9% | 2,000,000 | 0.0% | 0.02% | -10.0% | |
| ARGX | argenx SEsponsored adr | $2,261,000 | +6.6% | 100,000 | 0.0% | 0.02% | -5.3% | |
| Trillium Therapeutics Inc. | $2,131,000 | +17.1% | 413,697 | 0.0% | 0.02% | +6.2% | ||
| KRYS | New | Krystal Biotech, Inc. | $1,994,000 | – | 200,000 | +100.0% | 0.02% | – |
| DVAX | Dynavax Technologies Corporation | $1,613,000 | +122.8% | 75,000 | 0.0% | 0.01% | +116.7% | |
| JNCE | Jounce Therapeutics, Inc. | $1,558,000 | +11.0% | 100,000 | 0.0% | 0.01% | +8.3% | |
| CLLS | Cellectis S.A.sponsored ads | $1,423,000 | +10.2% | 50,000 | 0.0% | 0.01% | +9.1% | |
| IMDZ | Immune Design Corp. | $1,541,000 | +6.1% | 148,937 | 0.0% | 0.01% | -7.7% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $1,439,000 | -28.1% | 741,665 | 0.0% | 0.01% | -33.3% | |
| MDWD | MediWound Ltd. | $1,209,000 | -21.3% | 226,000 | 0.0% | 0.01% | -23.1% | |
| ABUS | Arbutus Biopharma Corporation | $1,120,000 | +72.3% | 180,582 | 0.0% | 0.01% | +50.0% | |
| RTTR | Buy | Ritter Pharmaceuticals, Inc. | $980,000 | +345.5% | 2,800,000 | +600.0% | 0.01% | +300.0% |
| AFMD | Affimed N.V. | $900,000 | +9.8% | 400,000 | 0.0% | 0.01% | 0.0% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $819,000 | +82.4% | 100,000 | 0.0% | 0.01% | +75.0% | |
| FPRX | Five Prime Therapeutics, Inc. | $787,000 | +35.7% | 19,247 | 0.0% | 0.01% | +20.0% | |
| INFI | Infinity Pharmaceuticals, Inc. | $772,000 | -15.3% | 580,400 | 0.0% | 0.01% | -25.0% | |
| FLGT | Fulgent Genetics, Inc. | $599,000 | -25.0% | 125,000 | 0.0% | 0.01% | -28.6% | |
| PRTO | Proteon Therapeutics, Inc. | $597,000 | +31.2% | 298,591 | 0.0% | 0.01% | +25.0% | |
| NVIV | InVivo Therapeutics Holdings Corp. | $580,000 | -46.3% | 400,000 | 0.0% | 0.01% | -44.4% | |
| BDSI | BioDelivery Sciences International, Inc. | $620,000 | +5.4% | 210,021 | 0.0% | 0.01% | 0.0% | |
| MTEM | New | Molecular Templates, Inc. | $505,000 | – | 72,412 | +100.0% | 0.00% | – |
| CCXI | ChemoCentryx, Inc. | $364,000 | -20.7% | 49,064 | 0.0% | 0.00% | -25.0% | |
| TTOO | New | T2 Biosystems, Inc. | $420,000 | – | 100,000 | +100.0% | 0.00% | – |
| BPMX | BioPharmX Corporation | $171,000 | -40.4% | 598,758 | 0.0% | 0.00% | -66.7% | |
| CYCCP | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $98,000 | +19.5% | 13,253 | 0.0% | 0.00% | 0.0% | |
| TENX | Buy | Tenax Therapeutics, Inc. | $126,000 | +28.6% | 348,374 | +162.0% | 0.00% | 0.0% |
| BTXWS | BioTime, Inc.*w exp 10/1/201 | $4,000 | -42.9% | 20,084 | 0.0% | 0.00% | – | |
| BIVV | Exit | Bioverativ Inc. | $0 | – | -8,249 | -100.0% | -0.00% | – |
| CMRX | Exit | Chimerix, Inc. | $0 | – | -115,216 | -100.0% | -0.01% | – |
| CRBP | Exit | Corbus Pharmaceuticals Holdings, Inc. | $0 | – | -130,129 | -100.0% | -0.01% | – |
| PTN | Exit | Palatin Technologies, Inc. | $0 | – | -2,050,000 | -100.0% | -0.01% | – |
| MCRB | Exit | Seres Therapeutics, Inc. | $0 | – | -125,000 | -100.0% | -0.01% | – |
| JUNO | Exit | Juno Therapeutics, Inc. | $0 | – | -50,000 | -100.0% | -0.01% | – |
| RARE | Exit | Ultragenyx Pharmaceutical Inc. | $0 | – | -25,000 | -100.0% | -0.01% | – |
| ALDR | Exit | Alder BioPharmaceuticals, Inc. | $0 | – | -217,328 | -100.0% | -0.02% | – |
| ZGNX | Exit | Zogenix, Inc. | $0 | – | -185,290 | -100.0% | -0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.